Microbiologically stable pharmaceutical composition containing electrochemically activated saline and using it
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a microbiologically stable pharmaceutical composition containing an active agent specified in prostaglandins, and a carrier. The carrier contains an aqueous electrochemically activated saline containing 1 to 500 mg/l of free chlorine and having an oxidation-reduction potential from +150 to +1350 mV. The active agent is present in a phase separated from the electrochemically activated saline; the electrochemically activated saline is a hypochlorite solution.
EFFECT: invention refers to using the pharmaceutical composition for treating and/or preventing dry eye syndrome and for cleansing contact lenses.
14 cl, 5 tbl, 2 ex
The invention relates to pharmaceutical compositions comprising an active ingredient and a carrier in which the carrier includes an aqueous electrochemically activated salt solution.
Annolyte® or Imecalyte® is a neutral electrochemically activated salt solution, which is a highly effective disinfectant. This activated solution can be obtained by electrolysis of sodium chloride. It can be applied in areas such as disinfection, for example, workstations, tables, floor, etc., for cold sterilization procedures, in agriculture for the removal of microorganisms for cleaning and washing, swimming pools and even for the prevention of athlete's. Device for the production of electrochemically activated neutral salt solutions is described in EP-A-1 728 768 incorporated herein by reference. The applicant, however, has no knowledge of the application of such solutions as carriers in pharmaceutical compositions.
WO 2004/031077 discloses a device for producing a biological solution by the electrolytic treatment of aqueous salt solutions. The contents of this document are incorporated herein by reference.
WO 2005/065388 discloses an aqueous solution with a redox potential and its use as a means of sanitizing�and or for treatment of wounds. The contents of this document are incorporated herein by reference.
The subject of this invention is the use of an aqueous electrochemically activated salt solutions, in particular solutions of salts of hypochlorite, as carriers in pharmaceutical compositions. The pharmaceutical compositions preferably include at least two separate phases where the first phase includes the active ingredient and the second phase includes the media.
In a first aspect the present invention relates to pharmaceutical compositions comprising an active ingredient and a carrier in which the carrier includes an aqueous electrochemically activated salt solution with a content of free chlorine between 1 and 500 mg/l and a positive redox potential of between +150 and +1350 mV. The active ingredient is preferably physically separated from the media, for example, the active ingredient is present in a phase separated from the electrochemically activated salt solution. However, if the active ingredient is sufficiently stable in the presence of electrochemically active salt, a pharmaceutical composition may also consist of one phase, e.g. an aqueous solution.
In another aspect this invention relates to the use of an aqueous electrochemically activated salt solution with a content of free x�ora between 1 and 500 mg/l and a positive redox potential of between +150 and +1350 mV as a carrier for the manufacture of pharmaceutical compositions.
Aqueous electrochemically activated solution has a content of free chlorine (determined using amperometric measurements (DFD) in accordance with US 4278507 incorporated herein by reference), providing sufficient activity, such as disinfecting or antimicrobial activity, without a negative impact on the stability of the composition. The chlorine content can be adjusted by diluting the electrochemically activated salt solutions in relation to, for example, 1 part (volume) saline solution to 1 - 250 parts (by volume) physiologically suitable carrier, such as water, buffer or saline solution. Preferably, the chlorine content is from 1 to 500 mg/l, particularly preferably from 10 to 400 mg/l, and most preferably from 100 to 350 mg/L.
The redox potential of the electrochemically activated salt solution is at least about +150 mV, preferably at least +200 mV, more preferably +300 mV, even more preferably at least +400 mV, even more preferably at least +500 mV and up to +1330 mV, preferably up to +1200 mV. In some embodiments the redox potential is between +650 mV to +950 mV, especially from +700 to +900 mV. Electrochemically activated salt solution of predpochtitel�but is a solution of alkali metal hypochlorite, for example, a solution of lithium hypochlorite, sodium or potassium. More preferably, the solution is a sodium hypochlorite solution.
Electrochemically activated salt solution generally has a pH of 2-8. In some embodiments the pH may be from 2-5, for example, from 2-4, 2-3 or 2-2,8. In other embodiments the pH may be from 5 to 8, in particular from 5.9 to 7.6 and more specifically, from 6.7 to 7.4.
The content of chlorate and/or the content of chlorite is preferably below the toxic level, for example below 10 mg/L. in addition, the solution is preferably free from detectable amounts of radicals such as Oh radicals, and ozone. In addition, the solution is preferably free from heavy metal ions, e.g., ions from Mo.
The active ingredient may be any medicament suitable for use in humans or in veterinary medicine, for example, selected from hydrophilic active ingredients or of lipophilic agents. In some embodiments it is preferable that the active ingredient has been selected from lipophilic or amphiphilic ingredients, i.e. ingredients, with the distribution coefficient of butanol-water at least 0.5, preferably at least 1. In other embodiments the active ingredient is a hydrophilic ingredient such as a polysaccharide. For example, the active agent can be selected from agents for the treatment of�I glaucoma, for example, prostaglandins, such as latanoprost, beta-blockers, such as timolol, agents to reduce elevated intraocular pressure such as dorzolamide, agents for the treatment of dry eye syndrome (ophthalmic lubricants, such as hydroxypropylmethyl cellulose (polymer) and hyaluronic acid, and other pharmaceutically active agents.
Pharmaceutical composition of the present invention is stabilized against microbial degradation. Thus, the composition is suitable for multipurpose usage. Composition for multi-purpose applications may not even contain conventional preservatives.
The composition is resistant to microbial degradation preferably within 6 months, more preferably at least 12 months even when stored at room temperature. Preferably, the antimicrobial activity of electrochemically activated salt solution can be determined by measuring c×t concentration (C) and contact time (t) of the product in accordance with the method described Schleupen, GWF, 1996. Preferably, the value of c×t is 1 mg/l×min or less, more preferably 0.5 mg/l×min or less to obtain a reduction factor of 106against microorganisms, such as Pseudomonas aeruginosa and Legionella pneumophila.
The composition may be intended� for any type of application, for example, for local or systemic use. For example, the composition is intended for ophthalmic, intranasal, custom, local, pulmonary, mucosal, oral or intraperitoneal application, for example, for use by injection. Preferred compositions are intended for ophthalmic applications, for example for the treatment of glaucoma or dry eye syndrome.
In one preferred embodiment of the invention the pharmaceutical composition comprises a single phase comprising as an active ingredient, and electrochemically activated salt. In this embodiment the active ingredient is sufficiently resistant to degradation in the presence of chemically active salt. Suitable examples of active ingredients are polymers selected from polysaccharides and polymers of polyvinylpyrrolidone. Polysaccharides, for example, may be selected from cellulose or derivatives of cellulose, or of glycosaminoglycans, such as heparin, heparan-sulfate and hyaluronic acid. More preferably, the composition may include an ophthalmic lubricant and a carrier, wherein the carrier includes an aqueous electrochemically activated salt solution with a content of free chlorine, as described above, i.e., from 1 to 500 mg/ml, and redox potential, as described above, i.e., from +150 to +130 mV. Ophthalmic lubricant may be a polymer, e.g. a polysaccharide or a polyvinyl, for example, cellulose or cellulose derivative such as methylcellulose, or glycosaminoglycans, such as hyaluronic acid. Pharmaceutical composition is preferably a homogeneous aqueous solution. In this embodiment it is preferable that the composition is not present other active agents and/or preservatives. The composition in accordance with this embodiment can be used for the treatment and/or prevention of dry eye syndrome.
In another embodiment, the composition preferably forms at least two separate stages, in which the active agent is present in the first phase and electrochemically activated salt solution is present in the second phase, separated from the first phase. The first phase can be a solid suspended phase and a liquid hydrophobic phase or a solid or liquid phase having a barrier in relation to the second phase which is an aqueous phase comprising a carrier. Thus, the composition may be an emulsion, e.g. microemulsion, or liposomal composition, or microcapsular composition or dispersion in which the active ingredient may be emulsified or dispersed in the presence of the optional carrier, n�example, lipophilic carrier and/or surfactants, in aqueous media. The active agent can thus be physically separated from the electrochemically activated salt solution.
Particularly preferred are micro-emulsions, as described in EP 07 008 347.1 incorporated herein by reference.
In addition to the active agent and the electrochemically activated salt solution, the composition may contain other known ingredients, such as buffers, adjuvants, auxiliary agents, fillers, diluents, etc.
The composition of the invention can be used in human or in veterinary medicine.
Another aspect of this invention relates to the use of electrochemically activated salt solution described above, for cleaning contact lenses, for example, glass or plastic contact lens. In this embodiment, the solution may not contain any active agent or may include an active agent such as a polymer, as described above.
Another aspect of this invention relates to the use of electrochemically activated salt solution described above for washing body cavities, for example, as a solution for intranasal, ophthalmic, or custom application. In this embodiment, the solution may not contain any active Angora�and or may include an active agent, for example, a polymer as described above.
Further, the present invention is described in more detail using the following examples.
Example 1. Preparation and characterization of microemulsion with electrochemically activated saline solution as a carrier
1.1. The composition of test formulations
Prepared following microemulsions comprising 0,0050% latanoprost as the active ingredient. All percentages are mass.
1.2. The stability of latanoprost in the microemulsions IMECALYTE®
The stability of latanoprost in the microemulsions comprising electrochemically
activated salt solution (IMECALYTE®) as a carrier was determined by HPLC. As a comparison, we analyzed the stability of latanoprost in solutions IMECALYTE®.
The amount of latanoprost (µg/ml) after storage at room temperature for specified time periods was as follows:
The results showed that latanoprost is protected from degradation caused IMECALYTE® in the formulation of microemulsions ME and ME2. In contrast, latanoprost was unstable in solutions IMECALYTE®. 0.5% IMECALYTE® significant degradation was observed after two weeks. A 10% solution IMECALYTE® latanoprost completely destroyed in a few minutes.
1.3. Antimicrobial act�emergency supply
We analyzed the activity of microemulsions containing latanoprost against the growth of microorganisms Staphylococcus aureus and Pseudomonas aeruginosa. The initial concentration of S. aureus amounted 2,82×105/ml for ME and ME2, and 1.7×106/ml for M3 and ME. The initial concentration of P. aeruginosa was 2.15×106/ml for ME and ME2, and of 3.18×105/ml for M3 and of 3.18×106/ml for ME.
After 14 days it was observed viable microorganisms S. aureus and P. aeruginosa (concentration<10/ml) in ME, M3 and ME. In ME2 after 28 days was found organisms S. aureus. However, in ME the growth of P. aeruginosa was significantly inhibited.
The results of example 1 showed that the active ingredient, such as latanoprost, was protected from degradation in the microemulsions based on IMECALYTE®. In addition, these microemulsions exhibit significant antibacterial properties.
Example 2. Preparation and characterization of formulations of hyaluronic acid-based IMECALYTE®
Were prepared following the formulations of hyaluronic acid. All percentages are by mass percent.
Analyzed, does IMECALYTE® significant influence on the properties of the formulations, such as the droplet. The contact angle of drops separated control on the paper surface was measured immediately after production of formulations HS1 and HS2 and after XP�tion for three months at room temperature. For comparison, a formulation of hyaluronic acid corresponding to HS2 (but without IMECALYTE®).
The following results were obtained:
In addition, we determined the spreading of the separated drops of different formulations of hyaluronic acid immediately after production (t=0) and after storage for three months at room temperature (t=3 months).
The above results showed that IMECALYTE® has no significant effect on characteristics of separation drops formulations of hyaluronic acid. The quality of separation and the formation of drops of solutions based on IMECALYTE® was very good.
In addition, it was determined the antimicrobial activity of formulations of hyaluronic acid-based IMECALYTE®. As a test organisms used S. aureus (initial concentration 7,27×105ml) and P. aeruginosa (initial concentration of 1.29×106/ml). With the solution HS1 concentration of viable P. aeruginosa was below 102/ml after 6 hours. With S. aureus was not detectable viable organisms after 14 days. With recipes HS2 viable microorganisms P. aeruginosa was not determined 7 days later. Viable microorganisms S. aureus was not detectable after 14 days.
The above results showed that formulations of hyaluronic acid-based IMECALYTE� are stable and possess antimicrobial activity.
1. Microbiologically stable pharmaceutical composition comprising an active agent selected from prostaglandins, and a carrier, wherein the carrier includes an aqueous electrochemically activated salt solution with a content of free chlorine between 1 and 500 mg/l and a redox potential of between +150 and +1350 mV, and the active agent is present in a phase separated from the electrochemically activated salt solution, and electrochemically activated salt solution is a solution of hypochlorite.
2. A composition according to claim 1, in which the chlorine content is from 10 to 400 mg/l, in particular from 100 to 350 mg/L.
3. A composition according to claim 1, in which the redox potential is from +650 to +950 mV, in particular from +700 to +900 mV.
4. A composition according to claim 1, in which the electrochemically activated salt solution is a solution of sodium hypochlorite.
5. A composition according to claim 1 in which the hypochlorite solution has a pH from 2 to 8.
6. A composition according to claim 1, intended for ophthalmic, intranasal, custom, local, mucosal or oral application.
7. A composition according to claim 1, in which the active agent is present in the suspended solid phase, a liquid hydrophobic phase or a solid or liquid phase, with the barrier relative to the electrochemically activated salt solution.
8. A composition according to claim 1, yavlyayuschayasya or dispersion.
9. The use of an aqueous electrochemically activated salt solution with a content of free chlorine between 1 and 500 mg/l and a redox potential of between +150 and +1350 mV as a carrier for the manufacture of pharmaceutical compositions according to claim 1, wherein the electrochemically activated salt solution is a solution of hypochlorite.
10. The use of electrochemically activated salt solution with a content of free chlorine between 1 and 500 mg/l and a redox potential of between +150 and +1350 mV for cleaning contact lenses, and electrochemically activated salt solution is a solution of hypochlorite.
11. Microbiologically stable pharmaceutical composition comprising ophthalmic lubricant selected from polyvinylpyrrolidone, cellulose, hydroxypropylmethylcellulose or hyaluronic acid, and a carrier, wherein the carrier includes an aqueous electrochemically activated salt solution with a content of free chlorine between 1 and 500 mg/l and a redox potential of between +150 and +1350 mV, and the electrochemically activated salt solution is a solution of hypochlorite.
12. A composition according to claim 11, which represents an aqueous solution.
13. A composition according to claim 11, containing additional active agents and/or preservatives.
14. Use of the composition according to claim 11 for the treatment and/or prophylaxis of syndrome dry�about the eyes.
SUBSTANCE: native amniotic membrane is placed into a storage solution containing BSS, gentamicin sulphate, amphotericin B, riboflavin. The amniotic membrane is placed into a sterile container and exposed to ultraviolet light; the ultraviolet exposure is combined with riboflavin instillations. The treated amniotic membrane is placed into the solution containing BSS, gentamicin sulphate, amphotericin B.
EFFECT: increasing the mechanical strength and biological properties of the amniotic membrane for the purpose of increasing the keratoplasty efficacy.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to pharmaceutical compositions, in particular to pharmaceutical composition, recovering visual pigment in case of insufficiency of endogenic 11-cis-retinal, which contains effective quantity of retinal derivatives and pharmaceutically acceptable carrier, where retinal derivative is converted into retinal, capable of forming functional complex opsin/retinal, where retinal derivative represents ester of 9-cis-retinyl of formula
ester of 11-cis-retinyl of formula or their combination, where A in each case stands for CH2OR and R represents ester-forming carboxylate radical of monocarboxylic acid C1-C10 or polycarboxylic acid, selected from oxalic acid, succinic acid, malic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, citric acid, ketoglutaric acid, fumaric acid, malonic acid and oxalacetic acid, which is substituting group in ester, where 11-cis-retinal insufficiency is caused by mutation in genes, coding proteins RPE65 and LRAT.
EFFECT: invention relates to method of recovering photoreceptor function or attenuation of loss of photoreceptor function; and to application of said retinal derivative for drug manufacturing.
43 cl, 7 dwg, 5 ex
SUBSTANCE: method involves performing a vitrectomy with removing a posterior hyaloids of a vitreous body, and a laser retinal endocoagulation at wave length 532 nm, emitting power 120-200 mWt, pulse length 0.1-0.2 s, spot diameter 150-200 mcm. A chorioretinal venous anastomosis (CRVA) is induced by exposing the branches of the central vein of the retina to the third-order laser light at wave length 532 nm in a number of 4 coagulated, emitting power 500 mWt, pulse length 1 sec and spot diameter 50 mcm. The vitrectomy is preceded by the intramuscular injections of 12.5% etamylate 4ml and the intravenous administration of 0.5% tranexamic acid 1 g 25-30 minutes before. That is followed by the droplet intravenous administration of an infusion solution containing 0.1% perlinganit 10 ml in 0.9% normal saline 100 ml at an initial rate of 5 mcg/min. The area to be exposed to laser is specified at least in 3 diameters of the disk from the optic disk. The third-order laser applications are applied on the branches of the central vein of the retina in a number from 2 to 4 at wave length 532 nm, emitting power 300-400 mWt, exposure 0.5 s, spot diameter 500 mcm in two points in the proximal and distal direction from the CRVA induction point. Immediately before the CRVA induction, a salt-water infusion flow is increased until the central retinal artery starts pulsating. The surgical management is completed by plugging the vitreal cavity with 20% air-gas mixture SF6.
EFFECT: effective management of the clinical course of the retinal venous thrombosis by considerable reduction of postoperative haemophthalmias.
SUBSTANCE: agent contains riboflavin riboflavin mononucleotide and dextran in the following proportions, wt %: riboflavin mononucleotide 1.0; dextran 20.0; normal saline - the rest.
EFFECT: forming the stable pre-corneal sustained-action colouring film, additional therapeutic activity of active substances and additives.
SUBSTANCE: what is presented is a kit for corneal saturation with a photosensitiser. The kit comprises a porous coating impregnated with 0.1% riboflavin and fitting the size of the corneal surface. The kit also comprises a coating fixation instrument comprising a semispherical umbrella-shaped base of 10-11.5 mm in diameter, 7.5-8.0 mm in radius of curvature, and a holder handle.
EFFECT: using the kit simplifies and accelerates the procedure of corneal saturation with the photosensitiser and reduces the time for the corneal collagen cross-linking procedure.
2 cl, 2 dwg, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to quinolines substituted by phosphorus-containing group of formula and applicable in medicine, wherein Z represents V1 and V2 are independently specified in hydrogen or halogen; one of R and R` represent phosphorus-containing substitute Q; the other one is specified in hydrogen or methoxyl; wherein the phosphorus-containing substitute Q represents A represents O; L represents C1-6alkyl; J represents NH or C3-6heterocycloalkyl and J is optionally substituted by G3; X is absent or represents -C(=O)-; X is absent or represents C1-6alkyl; each of R1 and R2 are independently specified in C1-6alkyl or C1-6alkoxy; G3 represents C1-6alkyl, R3S(=O)m-, R5C(=O)- or R3R4NC(=O)-; R3, R4 and R5 are independently specified in 3 or C1-6alkyl; m is equal to 0-2.
EFFECT: there are presented new protein kinase inhibitors effective for treating the diseases associated with abnormal protein kinase activity.
20 cl, 42 ex, 8 tbl, 3 dwg
SUBSTANCE: invention refers to biotechnology, specifically to VEGF-A specific binding proteins, and can be used in medicine for treating pathological angiogenesis in mammals. The antiangiogenic protein contains one ankyrin recurrent domain consisting of a N-terminal capping module of ankyrin recurrence, a recurrent module presented by an ankyrin recurrent motif of the sequence 1D23G4TPLHLAA56GH7EIVEVLLK8GADVNA (SEQ ID NO:5), wherein 1 represents an amino acid residue specified in A, N, R, V, Y, E, H, I, K, L, Q, S and T; 2 is specified in S, A, N, R, D, F, L, P, T and Y; 3 is specified in T, V, S, A, L and F; 4 is specified in W, F and H; 5 is specified in P, I, A, L, S, T, V and Y; 6 is specified in W, F, I, L, T and V; 7 is specified in L or P and 8 is specified in A, H, N and Y; a recurrent module presented by an ankyrin recurrent motif of the sequence 1D23G4TPLHLAA56GHLEIVEVLLK7GADVNA (SEQ ID NO:1), wherein 1, 2, 3, 4, 5, 6 and 7 independently represents an amino acid residue specified in the group of A, D, E, F, H, I, K, L, M, N, Q, R, S, T, V, W and Y, and a C-terminal capping module.
EFFECT: invention enables producing an antiangiogenic binding VEGF-A165 with Kd less than 10-7 M protein, which inhibits binding VEGF-A165 to VEGFR-2.
12 cl, 4 dwg, 4 ex
SUBSTANCE: invention represents a composition for preventing and treating allergic conjunctivitis and keratoconjunctivitis, containing cromoglicic acid, boric acid and water-soluble polymers specified in a group of: carbomer, hypromellose, macrogol and polyvinylpyrrolidone with the components of the composition taken in specific relations, g in 1 ml of the mixture.
EFFECT: invention provides the better reduction of the inflammatory process and symptoms of the disease; there are also ensured ease of use with a smaller frequency of administration, prolonged action and no side effects.
SUBSTANCE: group of inventions refers to medicine, namely to ophthalmology, and aims at treating dry eye syndrome, for contact lens disinfection and remoistening. A sterile water-based ophthalmic composition contains poly(ethylene oxide)-poly(butylene oxide) block copolymer of formula (EO)m(BO)n and galactomannan. Herewith, m has an average value of 45, and n has an average value of 9 to 18. Said galactomannan represents guar or its derivative. Besides, presented are a method for treating dry eye syndrome and a method for disinfecting a contact lens with using the above composition. The other embodiment discloses a method for delivering a pharmaceutical agent into the eyes involving the local administration of a formulation containing one or more pharmaceutically active agents and the above composition into the eyes.
EFFECT: using the group of inventions enables ensuring the more effective application of the above composition by providing the additional stability of a lachrymal film of the composition.
19 cl, 6 tbl, 29 dwg, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, namely to ophthalmology, and aims at treating macular degeneration in a mammal. A pharmaceutical composition for treating macular degeneration in a mammal contains an effective amount of 13,14-dihydro-15-keto-20-ethyl-prostaglandin F2α isopropyl ester. The above ophthalmic composition is presented in the form of eye drops, which are sterile, preservative-free as a single-use dosage form. What is also provided is a method of treating macular degeneration in a mammal that involves administering an effective amount of 13,14-dihydro-15-keto-20-ethyl-prostaglandin F2α isopropyl ester into an individual in need thereof.
EFFECT: using declared group of inventions provides effective treatment of macular degeneration in a mammal.
11 cl, 1 tbl, 2 dwg, 2 ex
SUBSTANCE: invention relates to active compositions for external application. An aqueous composition suitable for local application and adapted for external application on an animal contains: dicyclanil in polymorphic form A or B; a sodium lignosulphonate hydrophilic ionic surfactant; propylene glycol or polypropylene glycol; benzyl alcohol; a flow-inducing agent; citric acid and water, wherein the composition has pH 6.44-5.02. The composition can additionally contain an antiseptic agent selected from cetrimide and chlorhexidine gluconate; an odorant selected from a group consisting of pine and citronella; a dye selected from a group consisting of water-soluble dyes, organic contrast agents and titanium dioxide.
EFFECT: invention improves stability of the aqueous composition and efficiency of preventing and treating insect and flesh fly invasion, in infected or invasion-sensitive animals, particularly sheep.
7 cl, 3 dwg, 18 tbl, 7 ex
SUBSTANCE: invention relates to the beauty industry, representing a gel-like composition for topical application, containing salicylic acid with the concentration of ca. 17 wt %, elastic collodion in the amount of 5 to 10 wt % and ethyl lactate in the amount of 20 to 25 wt %, where the elastic collodion contains 65.8 wt % diethyl ether, 24.3 wt % ethanol, 2 wt % camphor, 3 wt % castor oil and 4.9 wt % nitro-cellulose.
EFFECT: invention provides excellent stability, even drying and the formation of a uniform film.
5 cl, 1 tbl, 4 dwg
SUBSTANCE: enzyme is coated with an internal envelope of a polycation and an external envelope of a polyanion, where the polycation used is protamine or polyarginine, the polyanion used is a block-copolymer of poly(glutamic acid) and polyethylene glycol, wherein the nanoparticle has a hydrodynamic diameter in the range of 40-70 nm. The invention also relates to a dispersion which contains nanoparticles of the antioxidant enzyme superoxide dismutase for medical use in the form of polyelectrolyte complexes of the type enzyme/polycation/polyanion, and a method of producing said dispersion.
EFFECT: high stability of the enzyme in a foreign medium with preservation of the activity of the enzyme.
9 cl, 1 dwg, 1 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to medicine and deals with pharmaceutical composition, containing suspension, which includes mixture of hydrophobic medium and solid form, where solid form contains therapeutically effective quantity of octreotide and, at least, one salt of fatty acid with medium chain length, which has chain length from 6 to 14 carbon atoms, and matrix-forming polymer, selected from dextran and polyvinylpyrrolidone (PVP), with salt of fatty acid with medium chain length being present in composition in amount of 10% by weight or more. Group of inventions also deals with capsule, containing said composition, intended for peroral introduction; method of obtaining said pharmaceutical composition.
EFFECT: group of inventions relates to improvement of octreotide bioavailability.
100 cl, 39 ex, 10 dwg, 45 tbl
SUBSTANCE: invention represents an agent for accelerating wound healing and tissue regeneration, containing oxymethyluracil, loratadine, sodium alginate, glycerol, a stabilising agent, a preserving agent and distilled water; the ingredients of the agent are taken in certain proportions, wt %.
EFFECT: accelerating wound healing and tissue regeneration, as well as possesses the pronounced immunomodulatory, anti-inflammatory, anti-allergic, anti-pruritic, anti-edematous and wound-healing action.
2 cl, 3 ex, 1 tbl
SUBSTANCE: invention represents an anti-inflammatory antibacterial wound-healing agent containing a polyethylene oxide base with molecular weight 400 (PEO-400) as a forming agent, as well as polyethylene oxide with molecular weight 1,500 (PEO-1500); an active substance is chloramphenicol and methyluracil; the agent is characterised by the fact that it additionally contains rifampicin and/or cycloserine; the cycloserine content in the rifampicin mixture is specified within the range of 18 to 82 wt %, whereas the ingredients are taken in certain ratio, wt %.
EFFECT: invention provides more effective healing of open wounds, ulcers, bedsores, as well as increased necrolytic effect, reduced exudation, and also a lower risk of allergic reactions.
3 cl, 9 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to pharmaceutical industry, namely to production of medications for treating dermatosis. Medication according to invention, made in form of cream, contains mometasone furoate, preservative, hydrophilic no-aqueous solvent, emulsifying agent of 1st kind, emulsifying agent of 2nd kind, emollient, disodium edetate (trilon B), pH-regulating agent, and purified water in quantities, given in invention formula.
EFFECT: invention can be applied for treating inflammatory diseases and itching in case of dermatosis, yielding to glycocorticosteroid therapy.
9 cl, 3 tbl, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry, and represents a pharmaceutical composition in the form of gel, which contains clindamycin phosphate, a combination of gel-forming polymer and hydrophilic dispersion phase, pH control agent, allantoin and lauryliminodipropionate sodium tocopheryl phosphate; the ingredients of the composition are taken in certain ratio, in g per 100 g.
EFFECT: invention provides the high level of antibacterial activity and stability.
5 cl, 1 tbl
SUBSTANCE: invention relates to a balanced fat composition, suitable for probe feeding. The fat composition, suitable for the probe feeding, contains from 8 to 15 wt % of linoleic acid (LA); from 3.0 to 6.0 wt % of a mixture, consisting of ω-3 polyunsaturated fatty acids, alpha-linolenic acid (ALA), docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), where the quantity of ALA>2.5 wt % and the mixed quantity of DHA and EPA≤2.5 wt %l from 10 to 20 wt % of at least one medium-chain fatty acid (MCFA); and from 35 to 79 wt % of one monounsaturated fatty acid (MUFA). Claimed is a liquid nutritional composition, containing the said fat composition. Claimed is a method of supplying enteral feeding to patients, which includes the introduction of an effective quantity of the said liquid nutritional composition, containing the balanced fat composition by the invention.
EFFECT: invention makes it possible to obtain the balanced nutritional composition for long enteral feeding.
27 cl, 1 dwg, 5 tbl
SUBSTANCE: invention can be used for the local treatment of trophic ulcers, infected and persistent septic wounds, degrees I-II-IIIA burns, traumatic skin injuries, pyoinflammatory skin diseases, bed sores, etc. The invention refers to a preparation, which contains a streptocide powder 1-2.5 g, Ichthyol ointment 7-10 g and castol oil 87.5-92 ml.
EFFECT: reducing the length of treatment up to 14 days with no side effects.
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relate to field of pharmaceutics and deal with pharmaceutically stable compositions, which contain human antibody, specifically bound with human interleukine 6 (hIL-6R) receptor, where said human antibody is contained in concentration from 5 to 200 mg/ml and includes variable region of light chain with amino acid succession SEQ ID NO:26, histidine, arginine, sucrose, polysorbate.
EFFECT: group of inventions ensure considerable degree of antibody stability after storing for several months.
22 cl, 8 ex, 28 tbl, 4 dwg